Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid
- 1 August 1996
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 41 (1-2) , 121-130
- https://doi.org/10.1016/0168-3659(96)01362-4
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.Journal of Clinical Investigation, 1995
- Cationic Lipid Is Not Required for Uptake and Selective Inhibitory Activity of ICAM-1 Phosphorothioate Antisense Oligonucleotides in KeratinocytesJournal of Investigative Dermatology, 1994
- Characteristics of Oligonucleotide Uptake in Human Keratinocyte CulturesJournal of Investigative Dermatology, 1993
- Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?Science, 1993
- Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cellsBiochemistry, 1993
- Intracellular disposition and metabolism of fluorescently-labled unmodified and modified oligouncleotides microijjected into mammalian cellsNucleic Acids Research, 1993
- Use of Cationic Lipids to Enhance the Biological Activity of Antisense OligonucleotidesJournal of Liposome Research, 1993
- Therapeutic Applications of OligonucleotidesAnnual Review of Pharmacology and Toxicology, 1992
- Antisense c-myc Oligodeoxyribonucleotide Cellular UptakePharmaceutical Research, 1992
- Mechansism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkagesNucleic Acids Research, 1991